Segmental Reporting (Tables)

3 Months Ended

Mar. 31, 2015

Segment Reporting [Abstract]

Schedule of Segment Revenue from Major Products

3 months to	March 31,	March 31,
	2015	2014
	$’M	$’M
	___________	___________
VYVANSE	416.8	351.2
LIALDA/MEZAVANT	148.5	128.9
CINRYZE	148.1	85.6
ELAPRASE	125.0	128.6
REPLAGAL	97.5	114.3
ADDERALL XR	95.7	85.1
FIRAZYR	92.5	74.9
VPRIV	86.4	86.9
PENTASA	78.7	72.3
FOSRENOL	44.1	41.4
XAGRID	25.3	27.1
INTUNIV	17.4	82.3
GATTEX/REVESTIVE	14.9	-
Other product sales	32.3	29.5
	____________	____________
Total product sales	1,423.2	1,308.1
	____________	____________